About: COVID‐19 and Headache Medicine: A Narrative Review of Non‐Steroidal Anti‐Inflammatory Drug (NSAID) and Corticosteroid Use

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID‐19 and Headache Medicine: A Narrative Review of Non‐Steroidal Anti‐Inflammatory Drug (NSAID) and Corticosteroid Use Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID‐19 and Headache Medicine: A Narrative Review of Non‐Steroidal Anti‐Inflammatory Drug (NSAID) and Corticosteroid Use
Creator	Smith, Jonathan Singh, R Smith, J Singh, Rashmi Arca, ( Arca, Karissa Boes, C Boes, Christoper Chiang, C.-C Chiang, Chia-Chun Garza, I Garza, Ivan Kissoon, N Kissoon, Narayan Robertson, C Robertson, Carrie Rozen, Todd Schwedt, T Schwedt, Todd Starling, A Starling, Amaal Vanderpluym, J Vanderpluym, Juliana Whealy, M Whealy, Mark
Source	Medline; PMC
abstract	OBJECTIVE: To summarize the current literature on non‐steroidal anti‐inflammatory drug and corticosteroid use during the coronavirus disease 2019 (COVID‐19) pandemic, recognizing that these are commonly used treatments in the field of headache medicine. BACKGROUND: The use of non‐steroidal anti‐inflammatory drugs and corticosteroids in patients during the COVID‐19 pandemic has been a controversial topic within the medical community and international and national health organizations. Lay press and social media outlets have circulated opinions on this topic despite the fact that the evidence for or against the use of these medications is sparse. In the field of headache medicine, these medications are used commonly and both patients and clinicians may have questions or hesitations pertaining to their use during the COVID‐19 pandemic. METHODS: A detailed search of the scientific and popular literature was performed. RESULTS: There is limited literature pertaining to the safety of non‐steroidal anti‐inflammatory drugs and corticosteroids during the COVID‐19 pandemic. To date, there are no clear scientific data that preclude the use of non‐steroidal anti‐inflammatory drugs in the general population who may acquire COVID‐19 or in those acutely infected with the virus. Several health organizations have concluded that treatment with corticosteroids during active infection should be avoided due to concerns of prolonged viral shedding in the respiratory tract and the lack of survival benefit based on the data from past coronaviruses and influenza virus; specific exceptions exist including treatment for underlying asthma or chronic obstructive pulmonary disease, septic shock, and acute respiratory distress syndrome. CONCLUSION: Scientific information regarding the COVID‐19 pandemic is constantly evolving, and limited or contradictory information can lead to confusion for both patients and clinicians. It is recommended that prior to prescribing non‐steroidal anti‐inflammatory drugs and steroids for the treatment of headache, clinicians have open discussions with their patients about the potential risks and benefits of using these medications during the COVID‐19 pandemic. This manuscript summarizes the currently available evidence and understanding about these risks and benefits to help clinicians navigate such discussions.
has issue date	2020-07-10(xsd:dateTime)
bibo:doi	10.1111/head.13903
bibo:pmid	32648592
has license	no-cc
sha1sum (hex)	ed94a63409f4bb43be0d258b69695c340c38601e
schema:url	https://doi.org/10.1111/head.13903
resource representing a document's title	COVID‐19 and Headache Medicine: A Narrative Review of Non‐Steroidal Anti‐Inflammatory Drug (NSAID) and Corticosteroid Use
has PubMed Central identifier	PMC7404408
has PubMed identifier	32648592
schema:publication	Headache
resource representing a document's body	covid:ed94a63409f4bb43be0d258b69695c340c38601e#body_text
is schema:about of	named entity 'Narrative' named entity 'COVID-19' named entity 'commonly' named entity 'Objective' named entity 'coronavirus disease 2019' named entity 'COVID' named entity 'Non-Steroidal Anti-Inflammatory Drug' named entity 'COVID' named entity 'peritonsillar abscess' named entity 'steroids' named entity 'COVID' named entity 'migraine' named entity 'COVID' named entity 'COVID-19' named entity 'ICU' named entity 'COX-2' named entity 'intensive care unit' named entity 'COVID-19' named entity 'corticosteroids' named entity 'hypernatremia' named entity 'COVID-19 pandemic' named entity 'COVID-19 pandemic' named entity 'current literature' named entity 'NSAIDs' named entity 'medical conditions' named entity 'NSAIDs' named entity 'lower respiratory tract infections' named entity 'serologic testing' named entity 'NSAIDs' named entity 'corticosteroids' named entity 'dyspnea' named entity 'steroids' named entity 'migraine' named entity 'social distancing' named entity 'peer-reviewed' named entity 'headache' named entity 'NSAIDs' named entity 'ibuprofen' named entity 'effective dose' named entity 'health policies' named entity 'viral shedding' named entity 'NSAID' named entity 'ACE2' named entity 'steroids' named entity 'English language' named entity 'United Kingdom' named entity 'NSAIDs' named entity 'NSAIDs' named entity 'parenteral' named entity 'SARS-CoV' named entity 'COVID' named entity 'COVID-19 pandemic' named entity 'critically ill patients' named entity 'virus' named entity 'fever' named entity 'chief complaint' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software